In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma

Leuk Res. 2012 May;36(5):598-600. doi: 10.1016/j.leukres.2012.01.025. Epub 2012 Mar 2.

Abstract

It was recently confirmed that the diuretic agent ethacrynic acid (EA) inhibits Wnt/beta catenin signaling in myeloma. This study investigated the antitumor effect of EA in vivo in a murine myeloma model. In vivo, tumor growth was significantly reduced and overall survival significantly prolonged in mice treated with EA as compared to untreated mice. Interestingly, this effect was higher as compared to the effect by lenalidomide, a commonly used drug against myeloma. These results reveal a significant in vivo effect by EA against myeloma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Diuretics / therapeutic use*
  • Drug Therapy, Combination
  • Ethacrynic Acid / administration & dosage
  • Ethacrynic Acid / therapeutic use*
  • Humans
  • Lenalidomide
  • Mice
  • Mice, Inbred BALB C
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Wnt Signaling Pathway
  • beta Catenin / physiology

Substances

  • Diuretics
  • beta Catenin
  • Thalidomide
  • Lenalidomide
  • Ethacrynic Acid